This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Emanuel, S. Articles by Middleton, S. A. Search for Related Content PubMed PubMed Citation Articles by Emanuel, S. Articles by Middleton, S. A.

The In vitro and In vivo Effects of JNJ-7706621: A Dual Inhibitor of Cyclin-Dependent Kinases and Aurora Kinases

¹ Cancer Therapeutics Research, Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, New Jersey and ² Piedmont Research Center, Morrisville, North Carolina

Requests for reprints: Stuart Emanuel, Johnson & Johnson Pharmaceutical Research & Development, LLC, 1000 Route 202, Raritan, NJ 08869. Phone: 908-704-5815; Fax: 908-704-4996; E-mail: semanuel{at}prdus.jnj.com.

Modulation of aberrant cell cycle regulation is a potential therapeutic strategy applicable to a wide range of tumor types. JNJ-7706621 is a novel cell cycle inhibitor that showed potent inhibition of several cyclin-dependent kinases (CDK) and Aurora kinases and selectively blocked proliferation of tumor cells of various origins but was about 10-fold less effective at inhibiting normal human cell growth in vitro. In human cancer cells, treatment with JNJ-7706621 inhibited cell growth independent of p53, retinoblastoma, or P-glycoprotein status; activated apoptosis; and reduced colony formation. At low concentrations, JNJ-7706621 slowed the growth of cells and at higher concentrations induced cytotoxicity. Inhibition of CDK1 kinase activity, altered CDK1 phosphorylation status, and interference with downstream substrates such as retinoblastoma were also shown in human tumor cells following drug treatment. Flow cytometric analysis of DNA content showed that JNJ-7706621 delayed progression through G₁ and arrested the cell cycle at the G₂-M phase. Additional cellular effects due to inhibition of Aurora kinases included endoreduplication and inhibition of histone H3 phosphorylation. In a human tumor xenograft model, several intermittent dosing schedules were identified that produced significant antitumor activity. There was a direct correlation between total cumulative dose given and antitumor effect regardless of the dosing schedule. These results show the therapeutic potential of this novel cell cycle inhibitor and support clinical evaluation of JNJ-7706621.

This article has been cited by other articles:

				W. Berkofsky-Fessler, T. Q. Nguyen, P. Delmar, J. Molnos, C. Kanwal, W. DePinto, J. Rosinski, P. McLoughlin, S. Ritland, M. DeMario, et al. Preclinical biomarkers for a cyclin-dependent kinase inhibitor translate to candidate pharmacodynamic biomarkers in phase I patients Mol. Cancer Ther., September 1, 2009; 8(9): 2517 - 2525. [Abstract] [Full Text] [PDF]

				O. Fedorov, B. Marsden, V. Pogacic, P. Rellos, S. Muller, A. N. Bullock, J. Schwaller, M. Sundstrom, and S. Knapp A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases PNAS, December 18, 2007; 104(51): 20523 - 20528. [Abstract] [Full Text] [PDF]

				S. V. Sharma and J. Settleman Oncogene addiction: setting the stage for molecularly targeted cancer therapy Genes & Dev., December 15, 2007; 21(24): 3214 - 3231. [Abstract] [Full Text] [PDF]

				W. DePinto, X.-J. Chu, X. Yin, M. Smith, K. Packman, P. Goelzer, A. Lovey, Y. Chen, H. Qian, R. Hamid, et al. In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol. Cancer Ther., November 1, 2006; 5(11): 2644 - 2658. [Abstract] [Full Text] [PDF]

				J. A. Seamon, C. A. Rugg, S. Emanuel, A. M. Calcagno, S. V. Ambudkar, S. A. Middleton, J. Butler, V. Borowski, and L. M. Greenberger Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent kinase/Aurora kinase inhibitor. Mol. Cancer Ther., October 1, 2006; 5(10): 2459 - 2467. [Abstract] [Full Text] [PDF]

				K. R. LaMontagne, J. Butler, D. J. Marshall, J. Tullai, Z. Gechtman, C. Hall, A. Meshaw, and F. X. Farrell Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol. Cancer Ther., February 1, 2006; 5(2): 347 - 355. [Abstract] [Full Text] [PDF]